VIP Receptor & Signaling Pathways — Research Reference

Vasoactive Intestinal Peptide (VIP) exerts its pleiotropic effects primarily through G protein-coupled receptors (GPCRs), namely VPAC1, VPAC2, and PAC1, initiating diverse intracellular signaling cascades critical for various physiological and pathophysiological research models. These receptor-ligand interactions are central to understanding VIP’s documented involvement in immune modulation, neuroprotection, and vascular tone regulation within preclinical studies.

The extensive research interest in VIP receptor & signaling pathways is underscored by numerous indexed publications and several registered studies on ClinicalTrials.gov, highlighting its significance as a research target for understanding fundamental biological processes and exploring potential research compounds.

Introduction to Vasoactive Intestinal Peptide (VIP) as a Research Agent

Vasoactive Intestinal Peptide (VIP) is a fascinating endogenous neuropeptide belonging to the secretin-glucagon superfamily, initially isolated from porcine duodenum in 1970. Despite its name, which alludes to its early discovery and prominent vasodilatory effects, subsequent research has revealed VIP’s widespread distribution and multifaceted roles across numerous physiological systems. It acts as a neurotransmitter, neuromodulator, and hormone, exerting a broad spectrum of biological activities in the central and peripheral nervous systems, gastrointestinal tract, cardiovascular system, and immune system. The extensive investigation into VIP’s actions, documented across numerous PubMed publications and several ClinicalTrials.gov registered studies (primarily observational or mechanistic rather than interventional for human treatment), underscores its significance as a subject of rigorous scientific inquiry into fundamental biological processes.

As a research agent, VIP provides an invaluable tool for exploring complex cellular and systemic interactions. Its amphipathic nature allows it to interact with specific G protein-coupled receptors, initiating diverse intracellular signaling cascades. Researchers utilize VIP to elucidate mechanisms underlying various physiological and pathophysiological states, including neuroprotection, inflammation, immune regulation, and vascular tone. Understanding how VIP modulates these processes at a molecular and cellular level contributes significantly to the broader knowledge base of peptide signaling and its implications in biological systems. For researchers focused on peptide synthesis and characterization, understanding the full scope of VIP’s biological activity is crucial, and resources such as those on what are research peptides provide foundational context.

The classification of VIP as a vasoactive intestinal peptide provides a historical perspective, yet its utility in contemporary research extends far beyond its initial characterization. It serves as a prime example of a pleiotropic peptide, capable of eliciting distinct responses depending on the specific receptor subtype engaged, the cellular context, and the presence of other modulating factors. This complexity makes VIP an excellent subject for advanced mechanistic studies, allowing researchers to dissect specific signaling pathways and cellular outcomes. The availability of high-quality VIP for research purposes, often accompanied by comprehensive Certificates of Analysis (COA), ensures reproducibility and reliability in experimental designs, which is paramount for generating robust and verifiable scientific data.

VIP Receptors: Classification and Distribution in Research Models (VPAC1, VPAC2, PAC1)

The biological actions of Vasoactive Intestinal Peptide (VIP) are mediated through its interaction with specific G protein-coupled receptors (GPCRs), which belong to the B family of GPCRs. Three primary VIP receptors have been identified and extensively characterized in various research models: Vasoactive Intestinal Peptide Receptor 1 (VPAC1), Vasoactive Intestinal Peptide Receptor 2 (VPAC2), and Pituitary Adenylate Cyclase-Activating Polypeptide Type 1 Receptor (PAC1). While PAC1 exhibits a higher affinity for Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP), VIP can also bind to and activate PAC1, albeit with a lower affinity compared to VPAC1 and VPAC2. The distinct distribution patterns and pharmacological properties of these receptors contribute to the diverse physiological effects observed when VIP is applied in research settings.

VPAC1 Receptor Characteristics and Distribution

VPAC1, also known as VIPR1, is widely expressed across numerous tissues and cell types, making it a ubiquitous target for VIP’s actions in many research models. Key areas of high VPAC1 expression include the central nervous system (e.g., cerebral cortex, hippocampus), immune cells (e.g., T lymphocytes, macrophages, dendritic cells), the gastrointestinal tract (e.g., epithelial cells, smooth muscle), and various glands. In research models, VPAC1 activation is frequently associated with anti-inflammatory effects, neuroprotection, and modulation of epithelial cell function. It is primarily coupled to Gs proteins, leading to the activation of adenylyl cyclase and a subsequent increase in intracellular cyclic AMP (cAMP) levels, which serves as a critical second messenger in many experimental setups. However, studies also suggest potential coupling to Gq or Gi pathways in specific cellular contexts, indicating a more complex signaling repertoire than initially understood.

VPAC2 Receptor Characteristics and Distribution

VPAC2, or VIPR2, shares significant homology with VPAC1 but exhibits a more restricted tissue distribution. It is prominently found in the cardiovascular system (e.g., vascular smooth muscle cells), lungs, pancreas, liver, certain immune cell subsets (e.g., mast cells, specific T cell populations), and discrete regions of the central and peripheral nervous systems. In research, VPAC2 is largely implicated in processes such as vasodilation, bronchodilation, insulin secretion, and specific immune responses. Similar to VPAC1, VPAC2 primarily couples to Gs proteins, activating adenylyl cyclase and increasing cAMP production. The differential expression of VPAC1 and VPAC2 in various tissues allows researchers to investigate VIP’s pleiotropic effects by utilizing selective agonists or antagonists in experimental models to dissect specific physiological outcomes.

PAC1 Receptor Characteristics and Distribution

The PAC1 receptor (PACAP R1), while primarily known for its high affinity for PACAP, is also activated by VIP at higher concentrations, making it a relevant component of VIP signaling, particularly in contexts where PACAP and VIP co-exist or where PACAP is less abundant. PAC1 is highly expressed in the brain, especially in the hypothalamus, cerebellum, and brainstem, as well as in the pituitary gland, adrenal gland, and reproductive organs. In research models, PAC1 activation is strongly linked to neuroprotection, neuronal differentiation, regulation of hormone secretion, and specific responses to stress. Like VPAC1 and VPAC2, PAC1 typically couples to Gs proteins, leading to cAMP accumulation, but it also robustly couples to Gq proteins, activating phospholipase C (PLC) and subsequently increasing intracellular calcium concentrations and protein kinase C (PKC) activity. This dual coupling mechanism provides PAC1 with a distinct signaling profile that researchers leverage to explore the nuances of VIP’s actions in specific neuronal and endocrine models.

Downstream Signaling Pathways Activated by VIP Receptors (cAMP, PLC, MAPK, NF-κB)

The binding of Vasoactive Intestinal Peptide (VIP) to its G protein-coupled receptors (GPCRs)—VPAC1, VPAC2, and PAC1—initiates a complex interplay of intracellular signaling cascades. These pathways are crucial for translating extracellular VIP signals into diverse cellular responses, encompassing everything from gene expression modulation to rapid changes in cell metabolism and function. Understanding these downstream effectors is paramount for researchers aiming to delineate the precise mechanisms by which VIP exerts its pleiotropic actions in various biological systems. The primary pathways include cyclic AMP (cAMP) production, phospholipase C (PLC) activation, mitogen-activated protein kinase (MAPK) cascades, and the nuclear factor-kappa B (NF-κB) pathway.

cAMP Pathway Activation

The most well-characterized and robust signaling pathway activated by VIP receptors, particularly VPAC1 and VPAC2, is the Gs protein-cAMP pathway. Upon VIP binding, the receptor undergoes a conformational change, leading to the activation of stimulatory G proteins (Gs). The α-subunit of activated Gs then dissociates and stimulates adenylyl cyclase, an enzyme responsible for converting ATP into cyclic AMP (cAMP). Elevated intracellular cAMP levels activate protein kinase A (PKA), which in turn phosphorylates a wide range of target proteins, including ion channels, transcription factors, and other enzymes. This phosphorylation event can lead to diverse cellular outcomes such as smooth muscle relaxation, inhibition of inflammatory mediator release, modulation of gene expression (via CREB phosphorylation), and altered neuronal excitability in various research models. The extent of cAMP accumulation is often a direct measure used by researchers to assess receptor functionality and ligand potency.

Phospholipase C (PLC) Pathway Activation

While primarily known for Gs coupling, VIP receptors, particularly PAC1 and, to a lesser extent, VPAC1 and VPAC2 in specific contexts, can also couple to Gq proteins, leading to the activation of the phospholipase C (PLC) pathway. Activation of PLC-β hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into two key second messengers: inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 diffuses into the cytoplasm and binds to receptors on the endoplasmic reticulum, triggering the release of intracellular calcium stores, leading to a transient increase in cytosolic Ca2+ concentration. DAG, on the other hand, remains membrane-bound and activates protein kinase C (PKC) in conjunction with Ca2+. The activation of the PLC-Ca2+-PKC axis contributes to various cellular responses, including neurotransmitter release, cell proliferation, gene expression, and changes in membrane excitability, particularly in neuronal and endocrine research models.

MAPK Cascades (ERK, JNK, p38)

The Mitogen-Activated Protein Kinase (MAPK) pathways represent a crucial family of signaling modules that regulate fundamental cellular processes such as proliferation, differentiation, stress responses, and apoptosis. VIP receptor activation has been shown to modulate all three major MAPK pathways: Extracellular signal-regulated kinases (ERK1/2), c-Jun N-terminal kinases (JNK), and p38 MAPK. While the precise mechanisms vary, VIP can activate MAPKs through both cAMP-dependent (PKA-mediated) and cAMP-independent (e.g., Ca2+-dependent, transactivation of receptor tyrosine kinases) pathways. ERK activation by VIP is often associated with cell survival, proliferation, and differentiation, particularly in neuronal and immune cells. Conversely, JNK and p38 activation can be linked to stress responses, apoptosis, and inflammatory mediator production depending on the cell type and experimental conditions. Understanding VIP’s role in modulating these pathways is critical for discerning its complex effects on cellular fate and function.

NF-κB Pathway Modulation

Nuclear factor-kappa B (NF-κB) is a pivotal transcription factor that plays a central role in regulating immune responses, inflammation, cell survival, and proliferation. VIP has been widely recognized in research models for its ability to modulate NF-κB activity, often exerting anti-inflammatory effects by inhibiting NF-κB activation. While NF-κB is typically activated by pro-inflammatory stimuli, VIP signaling, primarily through cAMP/PKA pathways, can interfere with the upstream signaling events that lead to NF-κB activation or promote the synthesis of inhibitory proteins. Specifically, PKA activation can lead to the phosphorylation of IκB kinase (IKK) components or direct phosphorylation of NF-κB subunits, thereby preventing the degradation of IκB (inhibitor of NF-κB) and subsequent nuclear translocation of NF-κB. This modulation of the NF-κB pathway is a key mechanism through which VIP can suppress the expression of pro-inflammatory cytokines and chemokines, making it a significant focus in immune and neuroinflammatory research models.

VIP Receptor & Signaling in Immune System Research Models

Vasoactive Intestinal Peptide (VIP) stands as a prominent immunomodulator, with extensive research demonstrating its capacity to finely tune both innate and adaptive immune responses across various experimental models. The ubiquity of VPAC1 and VPAC2 receptors on a wide array of immune cells, including T lymphocytes, B lymphocytes, macrophages, dendritic cells, and mast cells, underscores VIP’s comprehensive involvement in immune regulation. Researchers utilize VIP to investigate mechanisms of immune suppression, anti-inflammatory actions, and the intricate balance between immune activation and tolerance. This makes VIP a critical tool for understanding immune system function and dysfunction in model systems relevant to inflammation, autoimmunity, and infection.

Modulation of T Lymphocyte Function

In research models, VIP exerts significant effects on T lymphocyte differentiation, proliferation, and cytokine production. Activation of VPAC1 and VPAC2 receptors on T cells, primarily through the cAMP/PKA pathway, typically leads to an inhibition of T cell proliferation and a shift in cytokine profiles. For instance, VIP has been shown to suppress the production of pro-inflammatory cytokines such as TNF-α, IFN-γ, and IL-6, while simultaneously promoting the expression of anti-inflammatory cytokines like IL-10. Furthermore, VIP can influence the differentiation of T helper cell subsets, often favoring the development of regulatory T cells (Tregs) or T helper 2 (Th2) cells over T helper 1 (Th1) or T helper 17 (Th17) cells, thus promoting an anti-inflammatory and tolerogenic environment in experimental settings. These findings highlight VIP’s potential as a research probe to study immune tolerance mechanisms.

Impact on Macrophage and Dendritic Cell Activity

Macrophages and dendritic cells (DCs) are crucial components of the innate immune system and play pivotal roles in antigen presentation and initiation of adaptive immune responses. Research has consistently demonstrated that VIP can modulate the functional phenotype of these cells. In macrophages, VIP, acting through VPAC1 receptors, can inhibit the production of pro-inflammatory mediators such as nitric oxide (NO), TNF-α, and IL-6, while promoting the expression of anti-inflammatory cytokines. This contributes to the resolution of inflammation in experimental models. For dendritic cells, VIP has been shown to suppress their maturation, reduce their capacity for antigen presentation, and inhibit the production of co-stimulatory molecules and pro-inflammatory cytokines. These effects suggest that VIP can limit excessive immune activation and promote immune tolerance by directly influencing the most potent antigen-presenting cells.

Regulation of Mast Cell and Microglial Responses

Mast cells, key players in allergic reactions and inflammatory responses, also express VIP receptors, particularly VPAC2. Research indicates that VIP can modulate mast cell degranulation and the release of histamine and other inflammatory mediators. Depending on the experimental context and the concentration, VIP can either inhibit or, in some cases, induce mast cell mediator release, suggesting a complex regulatory role. In the central nervous system, microglia, the resident immune cells of the brain, are also targets for VIP signaling. VIP, through VPAC1 activation, has been shown to suppress microglial activation and the subsequent release of neurotoxic and pro-inflammatory factors, such as NO, TNF-α, and IL-6. This anti-inflammatory action within the brain parenchyma is a significant area of investigation, especially in models of neuroinflammation and neurodegenerative conditions, positioning VIP as a valuable research agent in neuroimmunology studies.

VIP Receptor & Signaling in Vascular System Research Models

Vasoactive Intestinal Peptide (VIP) is widely recognized as a potent vasodilator, and its intricate signaling pathways play a critical role in regulating vascular tone, endothelial function, and vascular remodeling in various research models. The presence of VIP receptors, primarily VPAC2, on vascular smooth muscle cells (VSMCs) and endothelial cells throughout the cardiovascular system underpins its widespread effects on blood vessel physiology. Researchers frequently employ VIP to investigate mechanisms related to vasodilation, angiogenesis, and the regulation of vascular inflammation, providing insights into the fundamental processes governing circulatory health and disease states.

Vasodilatory Mechanisms

The most prominent vascular action of VIP is its potent ability to induce vasodilation, which has been extensively characterized in numerous *in vitro* and *in vivo* research models. Upon binding to VPAC2 receptors on vascular smooth muscle cells, VIP typically activates the Gs-cAMP-PKA pathway. The subsequent increase in intracellular cAMP levels and activation of PKA leads to the phosphorylation of various downstream targets, including potassium channels (e.g., KATP channels) and calcium channels. This results in hyperpolarization of the cell membrane, decreased intracellular calcium concentrations, and ultimately, the relaxation of vascular smooth muscle. Additionally, VIP can stimulate the production and release of nitric oxide (NO) from endothelial cells, which further contributes to vasodilation by activating guanylyl cyclase in VSMCs, leading to increased cGMP and subsequent relaxation. These mechanisms are crucial for researchers studying blood flow regulation and cardiovascular function.

Modulation of Endothelial Cell Function

Beyond its direct effects on smooth muscle, VIP also significantly influences endothelial cell function in research models. Endothelial cells express VPAC receptors, and their activation by VIP can lead to several important responses. As mentioned, VIP can stimulate NO production, which is a key regulator of vascular tone and also possesses anti-atherogenic properties. Furthermore, VIP has been shown to modulate the expression of adhesion molecules on endothelial cells, potentially reducing leukocyte adhesion and transmigration, thus playing a role in mitigating vascular inflammation. Research also suggests that VIP can promote endothelial cell survival and proliferation, contributing to processes like angiogenesis (the formation of new blood vessels). Understanding VIP’s intricate regulation of endothelial function is vital for studies focused on vascular repair, atherosclerosis, and other endothelial dysfunctions.

VIP in Vascular Inflammation and Remodeling Research

The anti-inflammatory properties of VIP, established in immune system research, also extend to the vascular context. In experimental models of vascular injury or inflammation, VIP has been shown to suppress the expression of pro-inflammatory cytokines and chemokines within the vascular wall. By modulating NF-κB signaling and other inflammatory pathways, VIP can mitigate the inflammatory responses that contribute to conditions like atherosclerosis and restenosis. Furthermore, VIP signaling may play a role in vascular remodeling, which involves structural changes in blood vessels in response to various stimuli. Research suggests VIP can influence the proliferation, migration, and extracellular matrix production by vascular cells, impacting the long-term structural integrity and function of arteries and veins. These findings position VIP as a valuable tool for investigating the pathogenesis and potential modulators of various vascular pathologies in a research setting.

Neurotrophic and Neuroimmune Research Applications of VIP Signaling

Vasoactive Intestinal Peptide (VIP) is an abundantly expressed neuropeptide within both the central and peripheral nervous systems, where it performs diverse functions critical for neuronal survival, development, and immune regulation. Its receptors, particularly VPAC1 and PAC1, are widely distributed throughout neuronal and glial cells, making VIP signaling a central focus in neurotrophic and neuroimmune research applications. Researchers leverage VIP as a tool to investigate mechanisms underlying neuronal protection, neurogenesis, synaptic plasticity, and the intricate interplay between the nervous system and the immune system, particularly in the context of neuroinflammation and neurodegenerative conditions.

Neurotrophic and Neuroprotective Effects

A significant area of VIP research focuses on its potent neurotrophic and neuroprotective properties. In various *in vitro* and *in vivo* models of neuronal injury, VIP has been demonstrated to promote neuronal survival and prevent apoptotic cell death. This is often mediated through the activation of its receptors, leading to the upregulation of anti-apoptotic proteins and the modulation of stress-activated signaling pathways like MAPK cascades (e.g., ERK pathway). VIP can also stimulate neurite outgrowth and enhance synaptic plasticity, suggesting a role in neuronal development, repair, and learning and memory processes in experimental settings. For instance, studies in cultured neurons and animal models show that VIP can counteract excitotoxicity, oxidative stress, and inflammation-induced neuronal damage, positioning it as an important research agent for understanding resilience in the nervous system.

Modulation of Neurotransmitter Systems and Synaptic Function

VIP acts as a neuromodulator, influencing the release and effects of other neurotransmitters. Research indicates that VIP can modulate the release of acetylcholine, glutamate, and GABA in different brain regions, thereby impacting a wide range of neurological functions. Its presence in various interneurons and projection neurons suggests a role in fine-tuning circuit activity. Furthermore, VIP signaling contributes to synaptic plasticity, the ability of synapses to strengthen or weaken over time, which is fundamental to learning and memory. Studies using VIP and its receptor-selective agonists/antagonists allow researchers to dissect the precise mechanisms by which neuropeptides can influence synaptic transmission and plasticity, offering insights into the molecular basis of cognitive functions and their potential disruption in neurological disorders.

Neuroimmune Regulation and Anti-Neuroinflammatory Actions

The nervous system and immune system are intimately connected, and VIP plays a crucial role at this interface, particularly in the context of neuroinflammation. As discussed previously, VIP receptors are expressed on glia (astrocytes, microglia) and neurons, and VIP can exert significant anti-inflammatory effects. In models of neuroinflammation, VIP, primarily via VPAC1, has been shown to suppress microglial activation and the subsequent production of pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6), chemokines, and reactive oxygen/nitrogen species. By inhibiting NF-κB and activating the cAMP/PKA pathway, VIP can reduce the inflammatory burden within the central nervous system. This neuroimmune modulatory role is critically important for researchers investigating the progression of neurodegenerative diseases (e.g., Alzheimer’s, Parkinson’s) and neuroinflammatory conditions (e.g., multiple sclerosis, stroke), where uncontrolled inflammation contributes significantly to pathology.

Methodological Considerations for Studying VIP Receptor Interactions In Vitro and In Vivo

Studying Vasoactive Intestinal Peptide (VIP) receptor interactions and downstream signaling pathways requires a robust methodological approach to ensure accurate and reproducible results. Researchers must carefully select techniques appropriate for their specific research questions, whether investigating receptor binding, functional activation, or physiological outcomes in complex biological systems. Adherence to strict quality control for research reagents and rigorous experimental design are paramount for obtaining meaningful data. These considerations are critical across both *in vitro* cellular models and more complex *in vivo* animal studies.

In Vitro Methodologies

For *in vitro* studies, a variety of techniques are employed to characterize VIP receptor interactions and their immediate downstream effects:

• Radioligand Binding Assays: These assays quantify receptor density and binding affinity using radiolabeled VIP or selective VIP receptor agonists/antagonists (e.g., [125I]-VIP). By incubating cell membranes or whole cells with varying concentrations of labeled and unlabeled ligands, researchers can determine dissociation constants (Kd) and maximum binding capacities (Bmax), providing critical pharmacological data.
• Functional Assays:
  • cAMP Accumulation Assays: Given that VPAC receptors primarily couple to Gs proteins, measuring intracellular cAMP levels (e.g., using ELISA, FRET-based sensors, or luminescence assays) is a common and sensitive method to assess receptor activation and ligand efficacy.
  • Calcium Flux Assays: For PAC1 receptors and certain VPAC receptor couplings to Gq, monitoring intracellular calcium transients using fluorescent calcium indicators (e.g., Fura-2, Fluo-4) can reveal receptor activation.
  • Reporter Gene Assays: Cell lines stably transfected with reporter genes linked to cAMP-responsive elements (CRE) or NF-κB response elements can provide a readout of pathway activation over longer periods.
• Protein Expression and Phosphorylation Analysis: Techniques like Western blotting and immunofluorescence are used to detect receptor protein expression and the phosphorylation status of key signaling proteins (e.g., PKA substrates, ERK, JNK, p38, IκB) downstream of VIP receptor activation.
• Gene Expression Analysis: RT-PCR and RNA sequencing allow researchers to quantify changes in mRNA levels of target genes regulated by VIP signaling pathways, providing insights into long-term cellular adaptations.

In Vivo Methodologies

Translating *in vitro* findings to *in vivo* systems requires additional considerations and specialized techniques:

Research using VIP in animal models often involves direct administration of VIP, its analogs, or receptor-selective agonists/antagonists through various routes (e.g., intravenous, intraperitoneal, intracerebroventricular, local tissue injection) to study its physiological effects. The choice of administration route depends on the specific

Frequently Asked Questions

What is Vasoactive Intestinal Peptide (VIP) in a research context?

VIP is a 28-amino acid neuropeptide belonging to the secretin-glucagon family, extensively studied for its multifaceted roles in various biological systems, particularly within immune, vascular, and neurological research models, where it acts as a signaling molecule.

How many distinct VIP receptors are recognized in preclinical research?

Preclinical research identifies three primary G protein-coupled receptors (GPCRs) for VIP: VPAC1 (VIP/PACAP receptor type 1), VPAC2 (VIP/PACAP receptor type 2), and PAC1 (PACAP-specific receptor type 1), each exhibiting distinct tissue distribution and signaling preferences in experimental models.

What are the primary signaling pathways activated by VIP receptor binding?

Upon VIP binding, VPAC1 and VPAC2 receptors predominantly activate adenylate cyclase, leading to increased intracellular cyclic AMP (cAMP) levels. PAC1 receptors can also activate cAMP but may also couple to phospholipase C (PLC) and modulate MAPK pathways, depending on the research model and specific cell types under investigation.

How do researchers differentiate between VPAC1 and VPAC2 receptor activation?

Researchers often utilize selective agonists and antagonists, alongside gene knockout or knockdown techniques in cellular and animal models, to discern the specific contributions of VPAC1 and VPAC2 receptors to observed cellular or physiological responses in a controlled research environment.

What role does VIP receptor signaling play in immune cell research?

In immune cell research, VIP receptor signaling is investigated for its immunomodulatory effects, including regulation of cytokine production, T-cell differentiation, macrophage activation, and antigen-presenting cell function, influencing both pro-inflammatory and anti-inflammatory pathways within experimental systems.

Are there commercially available reagents for studying VIP receptors?

Yes, numerous research-grade reagents are available, including synthetic VIP, VIP receptor-specific agonists and antagonists, antibodies against VIP receptors, and cell lines expressing specific VIP receptor subtypes, all intended for in vitro and in vivo preclinical research applications.

What are common experimental techniques for assessing VIP receptor activity?

Common techniques include ligand binding assays, reporter gene assays for cAMP or calcium signaling, Western blotting for phosphorylated signaling proteins, quantitative PCR for receptor mRNA expression, and functional assays measuring cellular responses like cytokine release or cell proliferation in research models.

Can VIP receptor signaling be implicated in vascular smooth muscle cell studies?

Yes, VIP receptor signaling is a focus in vascular smooth muscle cell (VSMC) studies, particularly concerning its role in vasodilation, proliferation, and migration processes. Activation of VPAC receptors in VSMCs often leads to relaxation, an effect modulated by the specific receptor subtype and downstream cAMP signaling within a research context.

Scientific References

• PubMed: Vasoactive intestinal peptide
• ClinicalTrials.gov: Vasoactive intestinal peptide

All information from Royal Peptide Labs is provided for in-vitro laboratory and research use only — not for human, veterinary, diagnostic, or therapeutic use.